Interaction between advanced glycation end-products (AGEs) and their receptor (RAGE) plays a central role in diabetic nephropathy pathogenesis. Pathophysiological crosstalk between the AGEs-RAGE system and angiotensin II (Ang II) is also involved in this disease. This study investigated the role of proliferatoractivated receptor-g (PPAR-g)-modulating activity on inhibition of monocyte chemoattractant protein (MCP-1) expression. Telmisartan, an Ang II type 1 receptor blocker, downregulated RAGE mRNA and inhibited superoxide generation and MCP-1 gene expression in mesangial cells; these processes were blocked by GW9662, a PPAR-g inhibitor.
Interaction between advanced glycation end-products (AGEs) and their receptor (RAGE) plays a central role in diabetic nephropathy pathogenesis. Pathophysiological crosstalk between the AGEs-RAGE system and angiotensin II (Ang II) is also involved in this disease. This study investigated the role of proliferatoractivated receptor-g (PPAR-g)-modulating activity on inhibition of monocyte chemoattractant protein (MCP-1) expression. Telmisartan, an Ang II type 1 receptor blocker, downregulated RAGE mRNA and inhibited superoxide generation and MCP-1 gene expression in mesangial cells; these processes were blocked by GW9662, a PPAR-g inhibitor.
Candesartan, an Ang II type 1 receptor blocker, did not suppress AGEs-induced superoxide generation. Telmisartan and the antioxidant,
N-acetylcysteine, completely inhibited AGEs-induced MCP-1 overproduction by mesangial cells. These results suggest that telmisartan inhibits AGEs-signalling to MCP-1 expression in mesangial cells by downregulating RAGE gene expression and subsequent oxidative stress generation via PPAR-g activation.
This study has demonstrated a unique benefit of telmisartan in that it may function as an anti-inflammatory agent against AGEs via PPAR-g activation and may play a protective role in diabetic nephropathy.
Introduction
Diabetic nephropathy is a leading cause of end-stage renal disease, and accounts for disabilities and high mortality rates in patients with diabetes. 1 Development of diabetic nephropathy is characterized by glomerular hyperfiltration and thickening of glomerular basement membranes, followed by an expansion of the extracellular matrix in mesangial areas and an increased albumin excretion rate. 2 Diabetic nephropathy ultimately progresses to glomerular sclerosis associated with renal dysfunction. 2 Many types of study, such as in vitro experiments, pathological analyses and epidemiological studies, have shown that diabetic nephropathy is intrinsically an inflammatory disease. 3, 4 Indeed, several papers have reported that monocyte chemoattractant protein-1 (MCP-1), a principal chemokine that mediates the recruitment of monocytes to inflammatory sites, plays a central role in the pathogenesis of diabetic nephropathy. 5 -9 These observations suggest that inhibition of MCP-1 expression and consequent blockade of inflammatory reactions may be a novel therapeutic strategy for the treatment of diabetic nephropathy.
Reducing sugars can react nonenzymatically with the amino groups of protein to form Amadori products. 10, 11 These early glycation products undergo further complex reaction such as rearrangement, dehydration and condensation to become irreversibly cross-linked, heterogeneous fluorescent derivatives, termed advanced glycation-end products (AGEs). 10, 11 The formation and accumulation of AGEs have been shown to progress at an accelerated rate in diabetes. 10, 11 Recent understanding of this process has confirmed that the interaction between AGEs and their receptor (RAGE) generates oxidative stress and plays a role in altered gene expression of growth factors and cytokines, and is thus involved in the pathogenesis of diabetic nephropathy. 12, 13 In fact, there is compelling evidence that the formation and accumulation of AGEs mediates the progressive alteration of renal architecture and loss of renal function in diabetic nephropathy. 14 -16 Since the pathophysiological crosstalk between the AGEs-RAGE system and angiotensin II (Ang II) also plays a role in diabetic nephropathy, 17 -19 we examined here whether telmisartan, a unique Ang II type 1 receptor blocker with peroxisome proliferator-activated receptor-γ (PPAR-γ)modulating activity, could inhibit MCP-1 expression in AGEs-exposed human mesangial cells. 20 -22 Materials and methods MATERIALS Telmisartan was generously gifted by Boehringer Ingelheim (Ingelheim, Germany). The PPAR-γ inhibitor, GW9662, was purchased from Cayman Chemical (Ann Arbor, MI, USA). Bovine serum albumin (BSA) and the antioxidant Nacetylcysteine (NAC) were purchased from Sigma (St Louis, MO, USA). Candesartan was obtained from Toronto Research Chemicals Inc. (North York, Canada).
PREPARATION OF AGES-BSA
The AGEs-BSA was prepared as described previously by Yamagishi et al. 8 Briefly, BSA was incubated under sterile conditions with glyceraldehyde for 7 days. Unincorporated sugars were then removed by dialysis against phosphate-buffered saline. Control nonglycated BSA was incubated in the same way, except for the absence of reducing sugars. Preparations were tested for T Matsui, S Yamagishi, S Ueda et al. Telmisartan suppresses MCP-1 expression via PPAR-g endotoxin using the Endospecy ES-20S system (Seikagaku Co., Tokyo, Japan).
PREPARATION OF CELLS
Mesangial cells from human kidney were maintained in mesangial basal medium supplemented with 5% fetal bovine serum according to the supplier's instructions (Clonetics Corp., San Diego, CA, USA). The AGEs treatments were carried out in a medium containing 0.5% fetal bovine serum. Cells were used in the experiments after two to four passages.
PRIMERS AND PROBES
Sequences of the sense and antisense primers for detecting human RAGE mRNA were 5´-ATGGAAACTGAACACA GGCC-3´ and 5´-CACACATGTCCCCACC TTAT-3´, respectively, and for detecting human MCP-1 mRNA were 5´-AAC TGAAGCTCGCACTCTCG-3´ and 5´-TCAGC ACAGATCTCCTTGGC-3´, respectively. 8 The primers used for human β-actin mRNA detection were the same as described previously by Yamagishi et al. 8 
SEMI-QUANTITATIVE RT-PCR
Poly(A) + RNAs were isolated from cells treated for 4 h with one of the following: (i) nonglycated BSA; (ii) 100 µg/ml AGEs-BSA; (iii) 100 µg/ml AGEs-BSA in the presence of 100 nM telmisartan; or (iv) 100 µg/ml AGEs-BSA in the presence of 100 nM telmisartan plus 500 nM GW9662. Isolates were analysed by reverse transcription-polymerase chain reaction (RT-PCR) as described previously. 8 The amounts of poly(A) + RNA templates (30 ng) and cycle numbers for amplification (32 cycles for the RAGE gene, 30 cycles for the MCP-1 gene, and 23 cycles for the β-actin gene) were chosen in quantitative ranges where reactions proceeded linearly; these had been determined by plotting signal intensities as functions of the template amounts and cycle numbers. 8
DIHYDROETHIDIUM STAINING
Mesangial cells were treated for 4 h with one of the following: (i) non-glycated BSA; (ii) 100 µg/ml AGEs-BSA; (iii) 100 µg/ml AGEs-BSA in the presence of 100 nM telmisartan; (iv) 100 µg/ml AGEs-BSA in the presence of 100 nM telmisartan plus 500 nM GW9662; or (v) 100 µg/ml AGEs-BSA in the presence of 100 nM candesartan. The cells were then incubated with phenol red free Dulbecco's Modified Eagle Medium containing 3 µM dihydroethidium (DHE; Molecular Probes Inc., Eugene, OR, USA). After 15 min, the cells were imaged under a laser-scanning confocal microscope. For each sample, intensity of DHE staining in four different fields was analysed by microcomputer-assisted NIH Image (version 1.62) (National Institutes of Health, Bethesda, MD, USA).
MEASUREMENT OF MCP-1
Mesangial cells were treated for 24 h with one of the following: (i) non-glycated BSA; (ii) 100 µg/ml AGEs-BSA; (iii) 100 µg/ml AGEs-BSA in the presence of 100 nM telmisartan; or (iv) 100 µg/ml AGEs-BSA in the presence of 1 mM NAC. The amount of MCP-1 protein released into the media was then measured with an enzyme-linked immunosorbent assay kit (R & D Systems, Minneapolis, MN, USA) according to the manufacturer's instructions.
STATISTICAL ANALYSIS
All values were presented as means ± SE. One-way analysis of variance (ANOVA) followed by the Scheffe F-test was performed for statistical comparisons of the means of all the groups. A P value < 0.05 was considered to be statistically significant.
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Results
No endotoxin was detected in any of the cell preparations.
Since RAGE is a signal transducing receptor for AGEs 3, 12 we examined the effect of telmisartan on RAGE gene expression in AGEs-exposed mesangial cells. As shown in Fig. 1A , 100 nM telmisartan significantly (P < 0.01) inhibited the AGEs-induced upregulation of RAGE mRNA levels in mesangial cells and this inhibition was blocked (P < 0.01) by 500 nM GW9662, an inhibitor of PPAR-γ.
We examined whether telmisartan could 
Telmisartan suppresses MCP-1 expression via PPAR-g
inhibit the downstream signalling evoked by the AGEs-RAGE interaction by investigating the effect of telmisartan on intracellular reactive oxygen species (ROS) generation in AGEs-exposed mesangial cells. In this study, we employed DHE staining methods, because DHE is taken up by mesangial cells and is then converted to the fluorescent product, ethidium, in the presence of superoxide. 23 As shown in Fig. 1B , 100 nM telmisartan (P < 0.01), but not 100 nM candesartan, decreased the AGEs-elicited ROS generation in mesangial cells, and this inhibition was also blocked (P < 0.01) by 500 nM GW9662.
We further investigated whether telmisartan could inhibit the AGEs-induced MCP-1 gene expression in mesangial cells. As shown in Fig. 2A , AGEs-BSA at 100 µg/ml significantly (P < 0.01) upregulated MCP-1 In addition, 500 nM GW9662 blocked the inhibitory effects of telmisartan on MCP-1 gene expression in mesangial cells (P < 0.01). Moreover, telmisartan and the antioxidant, NAC (1 mM), were both found completely to inhibit (P < 0.01) the AGEs-induced MCP-1 overproduction by mesangial cells (Fig. 2B ).
Discussion
Recently, telmisartan, an Ang II type 1 receptor blocker, has been shown to have a unique property that activates PPAR-γ. 20 -22 Since activators of PPAR-γ not only improve insulin resistance by ameliorating carbohydrate and lipid metabolism, but also protect against oxidative stress-induced injury in vasculatures, 22, 24 telmisartan is a 'cardiometabolic sartan' that is thought to target both diabetes and cardiovascular disease in patients with hypertension. 21 In this study, we have extended these previous findings and demonstrated that telmisartan could block the AGEs-elicited MCP-1 induction in mesangial cells by suppressing RAGE gene expression and subsequent ROS generation via PPAR-γ activation.
In the early phase of diabetic nephropathy MCP-1 plays an important role in initiating monocyte recruitment to mesangial areas. 5 Plasma MCP-1 levels have been shown to be associated with albumin excretion rate, a marker of early diabetic nephropathy, in patients with type 1 diabetes. 6 Furthermore, the selective targeting of MCP-1 was recently shown markedly to decrease albuminuria, renal injury and fibrosis in streptozotocin-induced diabetic nephropathy. 7 Since candesartan, another Ang II type 1 receptor blocker, did not suppress the AGEs-induced ROS generation and GW9662, an inhibitor of PPAR-γ, completely blocked the inhibitory effects of telmisartan on RAGE gene expression and its downstream signalling in mesangial cells, the present study indicates that telmisartan has a unique beneficial effect; it could function as an antiinflammatory agent against AGEs by blocking the RAGE-mediated downstream pathways via PPAR-γ activation and may play a protective role in diabetic nephropathy.
The AGEs-RAGE interaction exerts pleiotropic actions on various types of cells by inducing the generation of intracellular ROS. 3, 12 In the present study, an antioxidant, NAC, completely inhibited the AGEs-induced MCP-1 overproduction by mesangial cells. In addition, we have found recently that an inhibitor of reduced nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, diphenylene iodonium, also inhibits upregulation of MCP-1 mRNA levels in AGEs-exposed mesangial cells. 9 These findings suggest that the NADPH oxidasederived ROS generation evoked by the AGEs-RAGE interaction may be a molecular target of telmisartan in AGEs-exposed mesangial cells.
Recently, PPAR-γ agonists have also been reported to downregulate RAGE expression in endothelial cells and, subsequently, inhibit the AGEs-induced MCP-1 expression, thus limiting cell susceptibility toward proinflammatory AGEs effects. 25 Taken together, the present observations suggest that telmisartan could directly modulate the development and progression of diabetic vascular complications due to its unique PPAR-γ-modulating activity.
